CORRECTION: Immunovia Interim Report, January-March 2019
(The previous release was sent at 10.23 CET and has been updated with accurate dates in the key indicators of the Swedish version. The correct dates refer to the years 2018 and 2019. Nothing else differs from the previous release.)During the first quarter of 2019, we remained focused on our product launch strategy and continued to create value, as we reached several key objectives and took several steps towards the commercialization of IMMray™ PanCan-d, our diagnostic test for early detection of pancreatic cancer. Another key objective that we reached in the first quarter was the